Our previous clinical study (Ribeiro et al., 2019) showed the effectiveness of Eriomin® in reducing fasting glucose, glucose intolerance, insulin resistance (HOMA‐IR), glycated hemoglobin (HbA1c), glucagon, C‐peptide, HSCRP, IL‐6, and TNF‐α. Here, TNF is linked to Glucose intolerance.